CN103735570A - 一种预防口腔真菌感染的口腔护理液 - Google Patents
一种预防口腔真菌感染的口腔护理液 Download PDFInfo
- Publication number
- CN103735570A CN103735570A CN201310755425.9A CN201310755425A CN103735570A CN 103735570 A CN103735570 A CN 103735570A CN 201310755425 A CN201310755425 A CN 201310755425A CN 103735570 A CN103735570 A CN 103735570A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- oral
- oral care
- care solution
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010061324 Oral fungal infection Diseases 0.000 title claims 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 12
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 8
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 6
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960002477 riboflavin Drugs 0.000 claims abstract description 6
- 229960003495 thiamine Drugs 0.000 claims abstract description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 6
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 6
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 6
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 6
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 6
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims abstract description 5
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract 3
- 229960000988 nystatin Drugs 0.000 claims abstract 3
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims abstract 3
- 239000007788 liquid Substances 0.000 claims description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229960003260 chlorhexidine Drugs 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical group [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- RRNIZKPFKNDSRS-UHFFFAOYSA-N Bensulide Chemical compound CC(C)OP(=S)(OC(C)C)SCCNS(=O)(=O)C1=CC=CC=C1 RRNIZKPFKNDSRS-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 208000007117 Oral Ulcer Diseases 0.000 claims description 2
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims 2
- 239000003765 sweetening agent Substances 0.000 claims 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 235000011511 Diospyros Nutrition 0.000 claims 1
- 244000236655 Diospyros kaki Species 0.000 claims 1
- 208000004179 Oral Leukoplakia Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000008369 fruit flavor Substances 0.000 claims 1
- SVYHKSYGLHIYEJ-UHFFFAOYSA-N n-chlorohexadecan-1-amine Chemical group CCCCCCCCCCCCCCCCNCl SVYHKSYGLHIYEJ-UHFFFAOYSA-N 0.000 claims 1
- 201000008557 oral mucosa leukoplakia Diseases 0.000 claims 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 4
- 230000000843 anti-fungal effect Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 208000024386 fungal infectious disease Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000000474 nursing effect Effects 0.000 description 15
- 206010017533 Fungal infection Diseases 0.000 description 11
- 208000031888 Mycoses Diseases 0.000 description 11
- 210000000214 mouth Anatomy 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 241000233866 Fungi Species 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 210000004400 mucous membrane Anatomy 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 206010006326 Breath odour Diseases 0.000 description 3
- 208000032139 Halitosis Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 206010003504 Aspiration Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- QZTLGJIUZACNEG-UHFFFAOYSA-N NCl.N1C=CC=C1 Chemical class NCl.N1C=CC=C1 QZTLGJIUZACNEG-UHFFFAOYSA-N 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种口腔护理液，其包含1～5%碳酸氢钠，0.006～0.02%维生素B1，0.003～0.02%维生素B2，0.0004～0.002%维生素B6，0.02～0.1%烟酰胺，0.002～0.01%泛酸钙，制霉素是50000-200000万单位/100kg，余量为水。本发明具广谱抗真菌作用，对念珠菌属的抗菌活性高，且局部用药浓度小，对肝肾功能不全的患者毒副作用小；本发明不仅可用于口腔局部感染的预防，还可用于真菌感染的治疗。
Description
技术领域
本发明涉及一种预防口腔真菌感染的口腔护理液，特别是一种能预防白血病、肝硬化、重型肝炎、消化道出血、肿瘤化疗后、系统性红斑狼疮和艾滋病等患者口腔真菌感染的口腔护理液，属于医药技术领域。
背景技术
人体口腔内寄居真菌等大量微生物，它们之间处于生物平衡状态，正常情况下不致病，对于白血病、肝硬化、重型肝炎、消化道出血、肿瘤化疗后、系统性红斑狼疮、艾滋病等患者因机体免疫力低下、药物干扰菌群平衡等原因，真菌容易侵入机体或异位而引起口腔感染。目前，临床上使用的漱口液种类繁多，常见的有5%碳酸氢钠溶液、复方氯已定含漱液、口洁灵等。这些漱口液应用范围广，适用于多种常见的口腔疾病，但这些口腔护理液用于预防口腔真菌感染并未取得特别明确和显著的效果。
发明内容
本发明的目的是提供一种预防口腔真菌感染的口腔护理液，该护理液对易造成口腔真菌感染患者的口腔健康起到预防和保护的作用，对已有口腔真菌感染的症状起到缓解作用，以克服现有的口腔护理液不能有效控制患者口腔真菌感染的不足。
本发明实现过程如下：
一种口腔护理液，包含以下组分，各组分重量百分含量为：1～5% 碳酸氢钠， 0.006～0.02% 维生素B1，0.003～0.02% 维生素B2， 0.0004～0.002% 维生素B6，0.02～0.1%烟酰胺，0.002～0.01% 泛酸钙，制霉素是50000-200000万单位/100kg，余量为水。
上述口腔护理液各组分优选的重量百分含量为：1～4% 碳酸氢钠， 0.006～0.018% 维生素B1，0.003～0.01% 维生素B2， 0.0004～0.0012% 维生素B6，0.02～0.06%烟酰胺，0.002～0.006% 泛酸钙，制霉素是50000-200000万单位/100kg，余量为水。
进一步的，上述口腔护理液还包含有0.05%-5% 甜味剂，1%-10% 增稠剂，0.05%-1% 香精，0.05%-0.3% 抑菌剂，0.01%-5% pH调节剂。所述增稠剂是甘油，甜味剂选自山梨醇、阿斯巴甜、糖精钠，香精选自L-薄荷脑或果味香精，抑菌剂选自西吡氯胺、洗必泰或SAP，pH调节剂选自磷酸二氢钠或磷酸氢二钠。
上述口腔护理液可预防或治疗口腔溃疡病、口腔黏膜白斑和口腔真菌感染。
本发明的优点及积极效果：
1、本发明具广谱抗真菌作用，对念珠菌属的抗菌活性高，且局部用药浓度小，对肝肾功能不全的患者毒副作用小；
2、本发明添加碳酸氢钠可以改变微生物的酸性环境，从而达到抑菌的目的；
3、本发明可防治口角炎、舌炎，有利于口腔粘膜的完整性；
4、本发明不仅可用于口腔局部感染的预防，还可用于真菌感染的治疗。
具体实施方式
下面结合实例对本发明的口腔护理液做详细说明。
本发明的口腔护理液是由具有抗真菌、改变口腔酸性环境、促进口腔黏膜生长为主要功效成分的西药辅以口感调配剂混合调制而成。
实施例1（以配制100kg为例）
碳酸氢钠 2%
制霉素 100000万单位
维生素B1 0.006%
维生素B2 0.005%
维生素B6 0.0006%
烟酰胺 0.03%
泛酸钙 0.003%
纯化水 余量。
实施例2（以配制100kg为例）
碳酸氢钠 4%
制霉素 50000万单位
维生素B1 0.018%
维生素B2 0.01%
维生素B6 0.0012%
烟酰胺 0.06%
泛酸钙 0.006%
阿斯巴甜 0.2%
甘油 8%
果味香精 0.2%
洗必泰 0.02%
磷酸二氢钠 0.4%
纯化水 余量。
实施例3（以配制100kg为例）
碳酸氢钠 3%
制霉素 200000万单位
维生素B1 0.009%
维生素B2 0.006%
维生素B6 0.0006%
烟酰胺 0.03%
泛酸钙 0.003%
山梨醇 3.0%
甘油 4.0%
L-薄荷脑 0.5%
西吡氯铵 0.04%
磷酸二氢钠 0.3%
纯化水 余量。
实施例4
选取志愿者共120例，这些志愿者分别为肝硬化、重型肝炎、消化道出血、肿瘤化疗后的患者，随机抽取，其中使用实施例2口腔护理液的志愿患者60例，另有志愿患者60例作为对照组使用复方氯己定漱口液，这两组患者每天各用各组选定口腔护理液进行漱口数次，共观察14天，观察结果表明：使用本发明口腔护理液的患者溃疡面不再发红的有55例，有效率为92%，其余5例改善效果不明显；使用过程中长有口腔黏膜白斑的有4例，有效率为93%，其余56例患者均未见口腔黏膜白斑生长；使用过程中咽拭子培养结果培养出真菌的有1例，有效率为98.3%，其余59例均未培养出真菌；口臭改善很明显的有60例，有效率为100%；。
使用复方氯己定漱口液的患者溃疡面不再发红的有40例，有效率为67%，其余20例改善效果不明显；使用过程中长有口腔黏膜白斑的有28例，有效率为47%，其余32例患者口腔内均长出1-3个大小不等的口腔黏膜白斑，或有白斑的未得到明显改善；使用过程中咽拭子培养结果培养出真菌的有8例，有效率为86.6%，其余52例未培养出真菌；口臭改善很明显的有60例，有效率为100%；。
总体来说，本发明对口腔真菌感染的预防和抑制较之复方氯己定漱口液有很明显的效果，平均有效率为98.3%，对口腔清洁及改善口腔异味有效率为100%。
Claims (7)
1.一种口腔护理液，其特征在于包含以下组分，各组分重量百分含量为：1～5% 碳酸氢钠， 0.006～0.02% 维生素B1，0.003～0.02% 维生素B2， 0.0004～0.002% 维生素B6，0.02～0.1%烟酰胺，0.002～0.01% 泛酸钙，制霉素是50000-200000万单位/100kg，余量为水。
2.根据权利要求1所述的口腔护理液，其特征在于各组分重量百分含量为：1～4% 碳酸氢钠， 0.006～0.018% 维生素B1，0.003～0.01% 维生素B2， 0.0004～0.0012% 维生素B6，0.02～0.06%烟酰胺，0.002～0.006% 泛酸钙，制霉素是50000-200000万单位/100kg，余量为水。
3.根据权利要求1所述的口腔护理液，其特征在于：包含有0.05%-5% 甜味剂，1%-10% 增稠剂，0.05%-1% 香精，0.05%-0.3% 抑菌剂，0.01%-5% pH调节剂。
4.根据权利要求3所述的口腔护理液，其特征在于：所述增稠剂是甘油，甜味剂选自山梨醇、阿斯巴甜、糖精钠，香精选自L-薄荷脑或果味香精，抑菌剂选自西吡氯胺、洗必泰或SAP，pH调节剂选自磷酸二氢钠或磷酸氢二钠。
5.权利要求1至4任意之一所述的口腔护理液在制备预防或治疗口腔溃疡病药物中的应用。
6.权利要求1至4任意之一所述的口腔护理液在制备预防或治疗口腔黏膜白斑药物中的应用。
7.权利要求1至4任意之一所述的口腔护理液在制备预防或治疗口腔真菌感染药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310755425.9A CN103735570A (zh) | 2013-12-13 | 2013-12-13 | 一种预防口腔真菌感染的口腔护理液 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310755425.9A CN103735570A (zh) | 2013-12-13 | 2013-12-13 | 一种预防口腔真菌感染的口腔护理液 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103735570A true CN103735570A (zh) | 2014-04-23 |
Family
ID=50492686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310755425.9A Pending CN103735570A (zh) | 2013-12-13 | 2013-12-13 | 一种预防口腔真菌感染的口腔护理液 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103735570A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107334781A (zh) * | 2016-05-02 | 2017-11-10 | 南昌市第九医院 | 一种用于预防和治疗口腔真菌感染的药物 |
| CN109513007A (zh) * | 2018-12-13 | 2019-03-26 | 中国人民解放军总医院 | 泛酸钙在制备抗菌消炎药物中的应用 |
| CN115192598A (zh) * | 2022-09-13 | 2022-10-18 | 山东百多安医疗器械股份有限公司 | 一种用于缓解口角炎的敷贴 |
| WO2024175393A1 (en) * | 2023-02-22 | 2024-08-29 | Unilever Ip Holdings B.V. | Toothpaste composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797262A (zh) * | 2009-02-05 | 2010-08-11 | 齐凤芹 | 一种治疗小儿口腔溃疡的西药散剂 |
-
2013
- 2013-12-13 CN CN201310755425.9A patent/CN103735570A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101797262A (zh) * | 2009-02-05 | 2010-08-11 | 齐凤芹 | 一种治疗小儿口腔溃疡的西药散剂 |
Non-Patent Citations (2)
| Title |
|---|
| 刘旭琴等: "两性霉素B联合碳酸氢钠漱口防治口腔真菌感染疗效观察", 《中华现代护理学杂志》, vol. 6, no. 18, 31 December 2009 (2009-12-31), pages 1667 - 1668 * |
| 李定印: "利多卡因加复合维生素B和制霉菌素治疗儿童口腔溃疡临床观察", 《实用医技杂志》, vol. 13, no. 12, 30 June 2006 (2006-06-30), pages 2178 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107334781A (zh) * | 2016-05-02 | 2017-11-10 | 南昌市第九医院 | 一种用于预防和治疗口腔真菌感染的药物 |
| CN109513007A (zh) * | 2018-12-13 | 2019-03-26 | 中国人民解放军总医院 | 泛酸钙在制备抗菌消炎药物中的应用 |
| CN115192598A (zh) * | 2022-09-13 | 2022-10-18 | 山东百多安医疗器械股份有限公司 | 一种用于缓解口角炎的敷贴 |
| WO2024175393A1 (en) * | 2023-02-22 | 2024-08-29 | Unilever Ip Holdings B.V. | Toothpaste composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vasudeva et al. | Disinfection of dentinal tubules with 2% Chlorhexidine gel, Calcium hydroxide and herbal intracanal medicaments against Enterococcus faecalis: An in-vitro study | |
| Ohshima et al. | A proposal of remedies for oral diseases caused by Candida: A mini review | |
| Reddy et al. | Role of ozone therapy in minimal intervention dentistry and endodontics-a review | |
| ES2565511T3 (es) | Composiciones antisépticas, procedimientos y sistemas | |
| Prajatelistia et al. | Tunicate‐inspired gallic acid/metal ion complex for instant and efficient treatment of dentin hypersensitivity | |
| Ximenes et al. | Antimicrobial activity of ozone and NaF-chlorhexidine on early childhood caries | |
| KR101653662B1 (ko) | 반대해 추출물을 유효성분으로 함유하는 구강질환 예방, 개선 또는 치료를 위한 조성물 | |
| JP2014028832A (ja) | 組織の殺菌又は消毒用製剤 | |
| Ibrahim et al. | Use of antibacterial nanoparticles in endodontics | |
| CN103735570A (zh) | 一种预防口腔真菌感染的口腔护理液 | |
| Akbulut et al. | In vitro antimicrobial activity of different electrochemicallyactivated solutions on enterococcus faecalis | |
| CN103932914A (zh) | 壳聚糖漱口液及其制备方法 | |
| JP2017534570A (ja) | 有機物質の存在下で改善された安定性を有するヨードフォア組成物 | |
| CN106456656A (zh) | 增强抗炎及杀菌力的用于预防及改善牙周病的组合物 | |
| Yoo et al. | Antifungal effects of synthetic human Beta-defensin-3-c15 peptide on Candida Albicans–infected root dentin | |
| CN108042420B (zh) | 一种用于口腔保健的组合物及其应用 | |
| Niu et al. | Efficacy of the dual-action GA-KR12 peptide for remineralising initial enamel caries: An in vitro study | |
| Zhao et al. | Mesoporous calcium-silicate nanoparticles loaded with Prussian blue promotes enterococcus faecalis ferroptosis-like death by regulating bacterial redox pathway ROS/GSH | |
| CN105213215A (zh) | 一种甲壳素护齿牙膏 | |
| CN107137273A (zh) | 一种口腔护理液 | |
| Manikyamba et al. | An evaluation of antimicrobial potential of irreversible hydrocolloid impression material incorporated with chitosan | |
| JP5108068B2 (ja) | 口腔内の細菌群を改善するラクトバシラス・ファーメンタムＳＧ−Ａ９５（ＬａｃｔｏｂａｃｉｌｌｕｓｆｅｒｍｅｎｔｕｍＳＧ−Ａ９５）及びその保健組成物 | |
| Anand et al. | A comparative analysis of antimicrobial property of wine and ozone with calcium hydroxide and chlorhexidine | |
| JP2014166992A (ja) | 口腔用組成物 | |
| CN107582737A (zh) | 一种复合洗必泰口腔消毒液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140423 |